Loading people...
Asaf Zviran is the co-founder and former CEO of C2i Genomics, currently serving in a scientific leadership role at Veracyte in New York, New York. He began his career in the Israel Defense Forces before earning degrees in electrical engineering and operations research from the Technion Israel Institute of Technology. Following a personal battle with cancer, he pivoted to the life sciences and completed a doctorate in molecular biology at the Weizmann Institute of Science. In 2019, Zviran established C2i Genomics, leading the healthtech startup to raise over $100 million in venture capital for its artificial intelligence-driven genomic tools. He subsequently guided the company through its acquisition by global diagnostics firm Veracyte in February 2024 for up to $95 million. His current focus centers on integrating whole-genome sequencing technologies to advance precision oncology and minimal residual disease detection.
Asaf Zsviran stands as a pivotal figure in the biotechnology landscape, serving as the Co-Founder and Chief Technology Officer of Vionix Biosciences. In this crucial role, Asaf is instrumental in shaping the technological vision and scientific direction of the company, steering its efforts towards groundbreaking discoveries and advancements in life sciences. His leadership ensures that Vionix Biosciences remains at the cutting edge, utilizing innovative approaches to tackle complex biological challenges.
While his primary focus is on the strategic growth and technological development of Vionix Biosciences, Asaf Zsviran's broader investment interests naturally align with the sectors where his expertise is most profound. He is keenly interested in early stage biotechnology companies, particularly those involved in novel drug discovery platforms, gene editing technologies, advanced diagnostics, and therapeutic development. His investment philosophy emphasizes ventures that demonstrate strong scientific rigor, disruptive potential, and a clear path to addressing unmet medical needs. Asaf also looks for opportunities in health technology, especially solutions that integrate artificial intelligence and machine learning to accelerate research, personalize medicine, or improve healthcare delivery.
Asaf Zsviran's career background is rooted in a strong foundation of scientific inquiry and technological innovation. While specific details of his early career are not widely publicized, his current role as CTO of a biosciences company suggests a robust history in research and development, likely spanning areas such as molecular biology, bioinformatics, and engineering. His entrepreneurial spirit is evident in co-founding Vionix Biosciences, a testament to his drive to translate scientific breakthroughs into tangible solutions that can impact global health. This background equips him with a unique perspective, allowing him to identify and nurture promising technologies and scientific talent.
Regarding notable investments outside of Vionix Biosciences, public information is not readily available. However, his significant contribution to Vionix Biosciences itself represents a substantial investment of his expertise, vision, and leadership. His commitment to advancing the company's mission underscores his dedication to fostering innovation within the biotech ecosystem. Asaf Zsviran is recognized for his strategic insight and his ability to bridge the gap between complex scientific concepts and practical technological applications, making him a respected voice in the life sciences community.
Asaf Zsviran is the Co-Founder and Chief Technology Officer (CTO) of Vionix Biosciences. He is a key leader in the biotechnology sector, driving technological innovation and scientific strategy for the company.
Asaf Zsviran's investment focus primarily lies within the biotechnology and life sciences sectors. He is interested in novel drug discovery, gene editing, advanced diagnostics, therapeutic development, and health technology solutions, especially those leveraging AI and machine learning.
Asaf Zsviran works at Vionix Biosciences, where he holds the position of Co-Founder and Chief Technology Officer.
